Search Results - "Dahlke, Frank"

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response by Kuhle, Jens, Kropshofer, Harald, Haering, Dieter A, Kundu, Uma, Meinert, Rolf, Barro, Christian, Dahlke, Frank, Tomic, Davorka, Leppert, David, Kappos, Ludwig

“…OBJECTIVETo assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its…”
Get full text

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study by Selmaj, Krzysztof, Prof, Li, David KB, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Stüve, Olaf, MD, Rieckmann, Peter, Prof, Montalban, Xavier, Prof, Ziemssen, Tjalf, MD, Auberson, Lixin Zhang, MD, Pohlmann, Harald, MSc, Mercier, Francois, PhD, Dahlke, Frank, MD, Wallström, Erik, MD

“…Summary Background Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to…”
Get full text

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis by Mallon, Ann-Marie, Häring, Dieter A, Dahlke, Frank, Aarden, Piet, Afyouni, Soroosh, Delbarre, Daniel, El Emam, Khaled, Ganjgahi, Habib, Gardiner, Stephen, Kwok, Chun Hei, West, Dominique M, Straiton, Ewan, Haemmerle, Sibylle, Huffman, Adam, Hofmann, Tom, Kelly, Luke J, Krusche, Peter, Laramee, Marie-Claude, Lheritier, Karine, Ligozio, Greg, Readie, Aimee, Santos, Luis, Nichols, Thomas E, Branson, Janice, Holmes, Chris

“…Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care…”
Get full text

How patients with multiple sclerosis acquire disability by Lublin, Fred D, Häring, Dieter A, Ganjgahi, Habib, Ocampo, Alex, Hatami, Farhad, Čuklina, Jelena, Aarden, Piet, Dahlke, Frank, Arnold, Douglas L, Wiendl, Heinz, Chitnis, Tanuja, Nichols, Thomas E, Kieseier, Bernd C, Bermel, Robert A

“…Patients with multiple sclerosis acquire disability either through: (1) Relapse-associated worsening (RAW), or (2) progression independent of relapse activity…”
Get full text

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis by Kuhle, Jens, Disanto, Giulio, Lorscheider, Johannes, Stites, Tracy, Chen, Yu, Dahlke, Frank, Francis, Gordon, Shrinivasan, Anupama, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Kappos, Ludwig

“…OBJECTIVE:We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with…”
Get full text

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials by Leppert, David, Kropshofer, Harald, Häring, Dieter A., Dahlke, Frank, Patil, Ashwini, Meinert, Rolf, Tomic, Davorka, Kappos, Ludwig, Kuhle, Jens

“…To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple…”
Get full text

Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses by Benedict, Ralph H.B., Tomic, Davorka, Cree, Bruce A., Fox, Robert, Giovannoni, Gavin, Bar-Or, Amit, Gold, Ralf, Vermersch, Patrick, Pohlmann, Harald, Wright, Ian, Karlsson, Göril, Dahlke, Frank, Wolf, Christian, Kappos, Ludwig

“…To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), by means of a…”
Get full text

Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials by Leppert, David, Kropshofer, Harald, Häring, Dieter, Dahlke, Frank, Patil, Ashwini, Meinert, Rolf, Tomic, Davorka, Kappos, Ludwig, Kuhle, Jens

Get full text

Application of the Parametric g-Formula to Characterizing Counterfactual Time-to-Event Disability Progression Outcomes in Multiple Sclerosis by Yiu, Sean, Wang, Qing, Mercier, Francois, Dahlke, Frank, Model, Fabian

Get full text

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study by Ziemssen, Tjalf, Piani-Meier, Daniela, Bennett, Bryan, Johnson, Chloe, Tinsley, Katie, Trigg, Andrew, Hach, Thomas, Dahlke, Frank, Tomic, Davorka, Tolley, Chloe, Freedman, Mark S

“…Defining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A…”
Get full text

Siponimod: From Understanding Mode of Action to Differentiation Versus Fingolimod (1536) by Bigaud, Marc, Tisserand, Sarah, Albrecht, Philipp, Zalc, Bernard, Hach, Thomas, Dahlke, Frank, Meier, Daniela Piani

“…Abstract only…”
Get full text

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis by Samjoo, Imtiaz A., Worthington, Evelyn, Haltner, Anja, Cameron, Chris, Nicholas, Richard, Rouyrre, Nicolas, Dahlke, Frank, Adlard, Nicholas

“…Background: Siponimod, interferon beta-1a (IFNβ-1a), IFNβ-1b and natalizumab have been evaluated as treatments for secondary progressive multiple sclerosis…”
Get full text

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study by D’Souza, Marcus, Yaldizli, Özgür, John, Roland, Vogt, Deborah R, Papadopoulou, Athina, Lucassen, Elisabeth, Menegola, Milena, Andelova, Michaela, Dahlke, Frank, Schnyder, Franz, Kappos, Ludwig

“…Background: To improve the consistency of standardized Expanded Disability Status Scale (EDSS) assessments, an electronic data capture tool and analysis tool…”
Get full text

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence by Hach, Thomas, Shakeri-Nejad, Kasra, Bigaud, Marc, Dahlke, Frank, de Micco, Massimiliano, Petricoul, Olivier, Graham, Gordon, Piani-Meier, Daniela, Turrini, Renato, Brinkmann, Volker, Nicoletti, Ferdinando

“…Maladjusted immune responses to the coronavirus disease 2019 (COVID-19), for example, cytokine release syndrome, may result in immunopathology and acute…”
Get more information

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis by Langdon, Dawn W., Tomic, Davorka, Penner, Iris‐Katharina, Calabrese, Pasquale, Cutter, Gary, Häring, Dieter A., Dahlke, Frank, Kappos, Ludwig

“…Background and purpose Studies reporting the baseline determinants of cognitive performance and treatment effect on cognition in patients with multiple…”
Get full text

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation by Dahlke, Frank, Arnold, Douglas L, Aarden, Piet, Ganjgahi, Habib, Häring, Dieter A, Čuklina, Jelena, Nichols, Thomas E, Gardiner, Stephen, Bermel, Robert, Wiendl, Heinz

“…Background: The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis aim to address unresolved questions in MS with a novel comprehensive…”
Get full text

Plasma Glial Fibrillary Acidic Protein Correlates with Characteristics of Advanced Disease and Treatment Response in Secondary Progressive Multiple Sclerosis (1782) by Kuhle, Jens, Kropshofer, Harald, Maceski, Aleksandra Maleska, Dahlke, Frank, Hach, Thomas, Tomic, Davorka, Kappos, Ludwig, Leppert, David

“…Abstract only…”
Get full text

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis by Samjoo, Imtiaz A., Worthington, Evelyn, Haltner, Anja, Cameron, Chris, Nicholas, Richard, Dahlke, Frank, Adlard, Nicholas

“…Background: Indirect treatment comparisons (ITCs) provide valuable evidence on comparative efficacy where head-to-head clinical trials do not exist; however,…”
Get full text

Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses by Samjoo, Imtiaz A., Worthington, Evelyn, Haltner, Anja, Spin, Paul, Drudge, Christopher, Cameron, Chris, Brennan, Róisín, Dahlke, Frank, Adlard, Nicholas

“…Head-to-head trials comparing siponimod with fingolimod or ofatumumab in patients with multiple sclerosis (MS) are lacking. Instead, the comparative efficacy…”
Get full text

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial by Arnold, Douglas L, Piani-Meier, Daniela, Bar-Or, Amit, Benedict, Ralph HB, Cree, Bruce AC, Giovannoni, Gavin, Gold, Ralf, Vermersch, Patrick, Arnould, Sophie, Dahlke, Frank, Hach, Thomas, Ritter, Shannon, Karlsson, Göril, Kappos, Ludwig, Fox, Robert J

“…Background: Magnetic resonance imaging (MRI) measurements of gray matter (GM) atrophy and magnetization transfer ratio (MTR; correlate of myelination) may…”
Get full text